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Abstract  
Advances in proteomics have fueled the search for novel cancer biomarkers with 
higher selectivity. Differential expression of low abundant proteins has been the usual 
way of finding those biomarkers. The existence of a selective receptor for each 
biomarker is compulsory for their use in diagnostic/prognostic assays. Antibodies are 
the receptors of choice in most cases although aptamers are becoming familiar 
because of their facile and reproducible synthesis, chemical stability as well as 
comparable affinity and selectivity. In recent years, it has been reported that the 
pattern of post-translational modifications, altered under neoplastic disease, is a 
better predictive biomarker than the total protein level. Among others, abnormal 
glycosylation is attracting great attention. Lectins and antibodies are being used for 
identification and detection of the carbohydrate moiety with low level of 
discrimination among various glycoproteins. Such level of selectivity is critical to bring 
next-generation biomarkers to the clinic. Aptamers that can be rationally tailored for a 
certain molecule domain can become the golden receptor to specifically detect 
aberrant glycosylation at each protein or even at each glycosylation site, providing new 
diagnostic tools for early detection of cancer. 
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1. Glycosylation: a distinctive feature of cancer 
The addition of carbohydrate moieties (glycans) to proteins in the endoplasmatic 
reticulum (N-linked glycans) or in the Golgi (O-linked glycans) is one of the most frequent post-
translational events along with phosphorylation [1]. In fact, between 70 and 80% of human 
proteins are glycosylated [2]. Protein synthesis is led by the genomic code but the functional 
properties are modulated by the glycan structure. A single protein can naturally carry different 
glycan chains, so they exist in several glycoforms, which confers a diversity of properties with 
important physiological implications. The presence of side sugar chains is particularly common 
in proteins located in the cell surface and in the extracellular matrix and has a decisive role in 
the cell communication including cell adhesion, signal trafficking, extravasation, metastasis or 
escaping from the immune system as well as in their stability (protection from proteases) [1]. 
The extension of protein glycosylation is dependent on the number of glycosylation sites in the 
protein sequence and the expression/activity of the enzymes involved, mainly 
glycosyltranferases and glycosidases, in the cell. The diverse and complex glycan structures, 
the glycome, make challenging their identification and quantitation, which is becoming 
essential to elucidate the significance in pathological conditions. 
The natural variety of glycans is extended during malignant transformation of cells 
when the normal glycosylation machinery is altered, for example up or down regulation of the 
enzymes involved, leading to changes in the chemical structure of the glycan (Figure 1). Main 
modifications are related to changes in linkage, hiperbranching of N-glycans or truncation of O-
glycans generating sialylated tumor antigens but not restricted to them. The level of 
glycosylation is also of paramount importance. The degree of occupancy at each site or the 
extension of the presence of defined structures such sialyl derivatives or core fucoses can vary. 
In fact, sialylation and fucosylation are the major glycosylation changes and their level is 
closely related with cancer biology through modulation of several biological processes [3, 4]. 
Though aberrant glycosylation is not included in the eight hallmarks of cancer there is a large 
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body of evidence showing that glycans are involved in the acquisition of all these distinct 
tumors capabilities [5]. Some of the glycosylation changes are only specific of tumors so these 
unique alterations in the glycosylation pattern may serve as a distinct feature of cancer cell, 
providing novel diagnostic tools. Therefore, the research attention is starting to move to 
clinically applicable glycan features to diagnose, predict recurrence/survival (prognostic) or 
predict the response to therapy to aid in the implementation of a personalized medicine.  
To date, the majority of FDA-approved cancer biomarkers are glycoproteins or tumor-
associated carbohydrate antigens (TACAs). In general, they lack sufficient specificity (absence 
of false positives). Even the most successful serum biomarker, the prostatic specific antigen 
(PSA) that was a milestone in the diagnostic of prostatic cancer, is not specific because it is 
elevated in benign diseases with a grey zone of diagnostic for values between the cut-off (4 
ng/mL) and 10 ng/mL. To improve sensitivity and specificity, the study of glycoforms of current 
biomarkers or of new ones is a promising approach. A successful case is the fucosylated α-
fetoprotein whose concentration in serum is more informative to discriminate hepatocellular 
cancer from other benign liver diseases than total α-fetoprotein itself [3]. Evidences of 
correlation between altered glycosylation and tumor initiation, progression, and metastasis 
pose a persistent analytical challenge, the development of specific analytical assays capable of 
recognizing the altered glycosylated target molecule as new means for early cancer diagnosis. 
Receptor-based assays, with emphasis in aptamer-assays that have especial potential to meet 
this challenge, are the focus of this feature. 
2. Receptors for glycan structures 
The discovery of novel serum biomarkers is of paramount importance to deliver 
personalized cancer therapies. However, once a potential biomarker is identified, the 
corresponding analytical method has to be developed for its use in routine clinical practice. 
While glicoprofiling studies rely on enzymatic restriction, chromatographic separation and 
mass spectrometry analysis [6], the point-of-care detection of a defined biomarker requires 
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other approaches. Ideally, detection methods should fulfill the ASSURED criteria (affordable, 
sensitive, specific, user-friendly, rapid and robust, equipment free and delivered to those who 
need it). To comply with it, receptor-based assays are the methods of choice for current 
biomarkers, mainly immunoassays. Usually, tumor biomarkers are in minute amounts 
surrounded by other proteins in concentrations several orders of magnitude higher. Therefore, 
high affinity biorecognition elements are needed to achieve the high sensitivity demanded. But 
the challenge to recognize a small portion of the glycan that is under/overexpressed in 
malignant cells is even more demanding, and the recognition of changes in glycosylation 
patterns requires novel and more specific receptors, specifically directed towards the glycan 
epitopes.  
Boronic acid derivatives recognize diols in the glycan structure (Figure 2) and have 
been used since mid-20th century but they have their own intrinsic preferences unless 
additional functionalities are added to confer extra selectivity [7].  
Nature also provides carbohydrate-reactive testing reagents, schematically 
represented in Figure 2. It is possible to obtain highly specific anti-carbohydrates monoclonal 
antibodies [8], although many interesting glycan peptides are conserved among species and, 
therefore may be non-immunogenic for the mammals that often serve as vehicles for the 
production of monoclonal antibodies. In consequence, other vertebrates more evolutionarily 
distant from humans have been explored to obtain carbohydrate-binding antibodies [9]. 
Furthermore, antibody-carbohydrate interaction is weaker than antibody-protein one limiting 
the sensitivity of the assays.  
Lectins, a large family of proteins of non-immune origin, are by far the most widely 
used receptor for glycan identification. They are isolated from natural sources in a great 
variety (hundreds) and show high selectivity toward defined glycosidic linkages between 
saccharides, thus providing structural information. They are the natural binders of 
carbohydrates in-vivo due to their multivalency though the overall affinity is modest (10-4-10-7 
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M) in comparison with antibodies. The source and purity of lectins could be an issue to obtain 
high quality data. These features along with moderate cross-reactivity make the development 
of glycan-peptide antibodies preferable for analytical developments.  
It is well recognized that neoplastic transformations nearly always imply alterations in 
glycan epitopes. However, many proteins secreted from tumor cells share similar changes in 
glycan expression. As an example above 650 core fucosylated (CF) sites were found in less than 
330 CF proteins in human sera or tumor cell lines but a small proportion (less than 50 
peptides) showed altered level of fucosylation to discriminate pancreatic cancer [10, 11]. This 
means that receptors must recognize the specific aberrant glycan at each specific site, that is, 
information from both carbohydrate and peptide chains is needed. Currently, those types of 
receptors are not available and directing antibodies to a certain region comprising both 
protein and glycan moieties is not an easy task. Meanwhile, mixed antibody (for protein 
recognition) and lectin (for glycan alteration recognition) ELISA-like assays have been 
developed [12]. 
3. Aptamers for cancer glycosylated biomarkers 
The ideal receptor for aberrant glycosylation such as core fucosylation should be capable 
of tightly bind both the amino acids near the glycosylation site and the glycan structure. 
Aptamers, single-stranded oligonucleotides obtained by an in vitro selection process to bind a 
specific target, have unique advantages to fulfil these requirements. Their small size, ∼13 kDa 
for a 40 nucleotides aptamer, may favor the access to glycan epitopes. They are selected in a 
versatile and purely (bio)chemical way, which can be designed to enhance the affinity to the 
subnM range as well as to drive it toward a defined region of interest through convenient and 
smartly designed counter selections steps. Once selected, they are obtained on larger scales 
than antibodies, by a chemical process that reduces the batch-to-batch variability that may 
lead to dramatically different results. In consequence, a variety of aptamers targeting different 
kind of carbohydrates such as monosaccharides, oligo- and poly-saccharides, aminoglycoside 
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antibiotics and glycoproteins have been described during the past quarter century [13, 14]. 
Despite sugars are not considered to be highly aptagenic because theirs structure has few 
charged groups and aromatic ring moieties, discrimination of a single functional group has 
been described for carbohydrate compounds. The aptamer for the aminoglycoside antibiotic 
neomycin B binds 100 times more weakly the analogue paramomycin (substitution of NH2 with 
OH) and its discrimination power remains when it is O-methylated to increase nuclease 
resistance in biological fluids [15].  
Right after discovery, the non immunogenic nature of aptamers boosts the interest as 
therapeutics molecules but also as a novel analytical reagent for diagnostics. Clinical targets 
were rapidly screened and aptamers for them are currently available [14]. Aptamers for 
potential tumor biomarkers including some of those approved for clinical usage have been also 
described. Two different approaches have been devised for the selection of aptamers 
recognizing these targets: i) using an individual purified form of the target or cell 
overexpressing the target; ii) raising aptamers against unknown abnormal targets on the 
surface of tumor cells. The latter strategy called Cell-SELEX is now preferred though it requires 
an extra effort if knowledge of the target is finally needed. For cancer diagnostics serum 
proteins are the preferential targets to keep in mind non-invasive monitoring, so the first 
strategy is the only option.  
Until now, most aptamers against glycoprotein biomarkers have been obtained 
without directing the selection towards any specific region of the target. Consequently, in 
most cases it is not known whether the glycan, the peptide or both are involved in the binding. 
The difficulty in fully characterize the aptamer-ligand complex is delaying this piece of relevant 
information. Thrombin aptamers are one of the few well characterized ones, though it is not a 
biomarker, and the glycosylated site is far from the aptamer recognition site [16]. Aptamers 
evolved against short synthetic peptides or recombinant proteins expressed in non-human 
cells cannot recognize the sugar chain because bacterial can not incorporate them. Only those 
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evolved using purified human proteins or recombinant peptides expressed in human cell lines 
might present such ability. However, until now, only a few aptamers were tested for sugar 
discrimination. An aptamer for epidermal growth factor receptor variant III EGFRvIII (uniquely 
expressed in glioblastoma) purified from E. coli did not show any binding affinity for its highly 
glycosylated human counterpart but resulted of therapeutic interest because can be 
internalized into the cell inducing apoptosis. The transfected aptamer blocks the 
unglycosylated form of EGFRvII recently synthesized inside the cell, which cannot undergo 
proper glycosylation reducing the amount of the cell membrane glycosylated protein, 
demonstrating that aptamers can disrupt post-translational modifications of proteins [17]. 
Aptamers have also shown the ability to distinguish between forms of the same 
protein with slightly different post-translational modifications. This is the case of the aptamer 
recognizing cyclophilin B (CypB), selected using as a target the secretome of pancreatic cancer 
instead of an individual target. The aptaassay developed using this aptamer as recognition 
element discriminated sera from pancreatic cancer patients and healthy volunteers but failed 
to correlate with the CypB levels detected by an immunoassay. This fact is attributed to the 
recognition by the aptamer of the human form of the protein but not the one expressed in 
bacteria while antibody interacts with both [18]. 
Ultimately, the success of obtaining very strong binders that differentiate subtle 
differences in glycans would depend on the availability of adequate glycopeptides. Initially, it 
was thought that conventional SELEX protocols cannot achieve such level of directed selection 
and carbohydrates alone were the target. In 2001 a RNA aptamer towards sialyl Lewis X 
antigen overexpressed in many tumors was evolved with a surprisingly low dissociation 
constant (Kd =3.3 nM) but the original DNA pool already had a relatively high affinity (Kd=170 
nM) [19]. Selectivity against other Lewis antigens was only 5 to 10 times. After this early 
success, aptamers derived against mono-, di- and oligosaccharides showed high dissociation 
constants because they lack charged groups or aromatic rings that are the source of 
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hydrophobic, ionic and hydrogen-bonding main interactions of aptamers with their ligands. 
Besides, the intrinsic flexibility of carbohydrate is less amenable to strong binding. More 
recently, unmodified RNA and DNA aptamers for negatively-charged sialic acid N-
acetylneuraminic acid (Neu5Ac) and a tumor-related derivative N-glycolylneuraminic acid 
(Neu5Gc) exhibited 1.35 [20] and 0.15 nM [21] affinity, respectively. They probably benefited 
from covalent immobilization instead of random binding of the target during selection to 
facilitate the convergence of sequences. The anti-Neu5Ac aptamer is about 60 times a stronger 
binder than the corresponding lectin; it also binds the derivative but about 70 times more 
weakly and it inhibits sialidase activity.  
Different variants of SELEX, summarized in Figure 3, have been recently explored to 
specifically drive the in vitro selection on the glycosylation site of the biomarkers. One 
possibility is the incorporation of a boronic acid-modified nucleotide (boronic acid-thymidine-
5’-triphosphate, B-TTP) into the DNA library to boost the affinity of the aptamers [22]. This led 
the selection toward the glycan part of fibrinogen (Kd in the low nM range) in contrast to the 
peptide-binding aptamer resulting from conventional SELEX (Kd=5 µM). Interestingly, random 
introduction of B-TTP into the aptamer selected without the boronic acid moiety does not 
improve the binding affinity. Although no consensus in the identified sequences was found, 
this is a general approach to target the selection to the glycan substructure of glycoproteins. 
Epitope-specific SELEX is another possibility to effectively select an aptamer against a 
region of a molecule. It is a special type of hybrid-SELEX, where first rounds are conventional 
performed and final rounds require a specific ligand competitor for elution. As an example, 
aptamers for the sialic acid receptor of hemagglutinin were evolved using a sialic acid-
containing protein (fetuin), so in the last rounds of selection only ssDNA bound to the sialic 
acid epitope in the receptor were eluted [23]. 
Synthesis of a short peptide containing the glycan can also serve as a target. One 
aptamer derived from such an approach targeted a recombinant five tandem repeats of 20 
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amino acid long peptide from mucin-1 that was synthetically O-glycosylated by 15 N-
acetylgalactosamine (Tn antigen), showing affinity for both regions, peptide and sugar regions, 
being the affinity for Tn more than one order of magnitude higher [24]. The reason for the 
preference for the Tn antigen is not explained but one can speculate that their abundance (15 
sugars) is the driving force. The contrary is held for aptamers derived from unglycosylated 
tandem peptide. This means that both types of aptamers bind a region near the glycosylated 
site, which is affected by the presence of the sugar. The use of synthetic peptides as targets 
allows the incorporation of counter-selection steps using a non-glycosylated synthetic variant, 
which is another possibility to direct aptamers towards the glycosylation site. This approach 
has been employed for the selection of a DNA aptamer that selectively bind an N-glycosylated 
peptide fragment of vascular endothelial growth factor (VEGF) [25]. Despite only one unit of N-
acetylglucosamine is incorporated at the natural glycosylation site of VEGF, the resulting 
aptamers show 52-fold selectivity towards the glycan-peptide over the non-glycosylated 
variant. In addition, the best aptamer is able to distinguish between peptide variants differing 
only by a single glycosylation site. However, this study does not show the feasibility of the 
aptamer to recognize native VEGF, which may adopt a three-dimensional conformation 
different form the peptide fragment. 
4. Future perspectives 
Deciphering the glycan signature of cancer is essential to early detection and to 
establish personalized therapies that increase the survival rate. The challenge is extremely 
demanding even in the post-genomic post-proteomic era. It implies characterization of 
hundreds of glycans and their abundancy as well as identification of glycosylation sites. Today, 
many of the exact structures attached to proteins found in serum are still unknown. With this 
purpose, receptors recognizing the glycosylation site and capable of differentiating minimal 
structural features are compulsory. As it was commented above, none of the existing receptors 
can provide the selectivity required. Rapid advancement in glycomics reveals new aberrant 
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alterations, which needs novel receptors. An example of this is the case of haptoglobin 
fucosylation associated to pathological conditions since several years. Recently, two 
fucosylation sites, in the core and in the sialyl determinant have been found [26]. In order to 
elucidate the significance of each one in any disease, specific detection is crucial. Many lectins 
recognize all types of linkages α1-3, 1-4 and α1-6 fucosylation (core), and the most widely 
used specific for core fucosylation also binds mannose residues. Though a natural lectin truly 
specific for core fucose was found only five years ago [27] there is no suitable receptors for the 
rest of fucose types.  
The development of synthetic receptors seems the most promising route to achieve 
the strict selectivity demanded. Since the biological importance of glycoproteins become clear, 
determined efforts are being performed to develop specific binders but there is substantial 
room for improvement. In this sense, aptamers could be a solution. Until now, aptamers 
selected against glycoproteins preferentially bind the peptide sequence unless a lot of identical 
sugars are present, so novel strategies directing it towards the glycan and its surrounded 
region are compulsory. Epitope-specific SELEX or availability of synthetic peptidoglycans can 
help in this task. Likewise, the synthesis of multiantennary glycans have progressed 
extraordinarily and now some of them are commercially available but unfortunately at not 
affordable fares. Moreover, the conjugation to the specific point in the peptide chain is a 
bottleneck for analytical chemists that need the highly purified peptidoglycan to develop 
better receptors. In achieving this, the availability of stronger and more specific binders will be 
increase.  
To improve the probability of identifying aptamers with high affinity towards the 
glycosylation site of glycoproteins it is also possible to use chemically modified nucleobases 
[28]. This is the case of the so-called SOMAmers (Slow Off-rate Modified Aptamers), which 
contain chemically modified deoxyuridine residues with modified side chains that increase the 
diversity of nucleic acids thus facilitating the selection of ligands with high affinity towards 
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proteins [29]. The use of high-throughput platforms such as SOMAscan [29], which has 
extraordinarily accelerated the discovery of protein biomarkers, may also be useful in the field 
of glycoproteins. It is conceivable that using different cross-linking chemistry aptamers 
recognizing proteins but also the carbohydrate moiety, so binding near the glycosylation site, 
could be developed with features as good as those found in SOMAmers for detecting proteins. 
Last but not least, fluent communication between analytical chemists and 
glycobiologists would speed up the development of improved receptors through helping 
chemists to early identify recognition sites of clinical/biological interest and promote less 
known synthetic receptors such as aptamers among clinicians or even pharmaceutical industry. 
The huge investment in antibodies since their discovery and the recent effort to humanize 
them to avoid the side effects have screened the potential of aptamers, which are ignored by 
the pharmaceutical and diagnostic-based industries. In the latest years, a blatant interest in 
aptamers is detected out of academia as a possibly solution to scientific challenges such as 
high degree of discrimination of minor changes not affordable with current antibodies or 
lectins. The detection of post-translational modifications, especially glycosylation as the most 
important one, is the next niche where aptamer must excel if they want to be widely 
recognized as a real alternative to antibodies and boost their commercialization. 
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CAPTION FOR THE FIGURES 
 
Fig. 1 Most common O- and N-linked protein glycosylation and changes (highlighted in 
pink) typically associated to malignant transformations of cells. GlcNAc, N-
acetylglucosamine. Fuc, fucose. Gal, galactose. Neu5Ac, 5-N-acetylneuraminic acid (sialic 
acid). GalNAc, N-acetylgalactosamine. Neu5GC, 5-N-glycolylneuraminic acid. Man, 
mannose 
Fig. 2 Synthetic (A, B) and natural (C,D) receptors for glycan structures. (A) Boronic acid 
derivative. (B) Aptamer. (C) Lectin. (D) Antibody 
Fig. 3 Different variant of SELEX procedure to drive the selection towards the glycosylation 
site of glycoproteins. (A) Use of boronic acid modified thymidine in the starting DNA 
library. (B) Elution with a specific ligand competitor in the last rounds of selection. (C) 
Counter-selection with a non-glycosylated target 
Graphical Abstract: Aptamers may specifically differentiate normal from aberrant 
glycoproteins. 
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